Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: Results from the cancer pain outcome research (CPOR) study group

Giovanni Apolone, Oscar Corli, Emanuele Negri, Simone Mangano, Mauro Montanari, Maria Teresa Greco

Research output: Contribution to journalArticle

Abstract

Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16% and 17%). About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.

Original languageEnglish
Pages (from-to)671-682
Number of pages12
JournalClinical Journal of Pain
Volume25
Issue number8
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Buprenorphine
Outcome Assessment (Health Care)
Pain
Opioid Analgesics
Neoplasms
Drug Evaluation
Fentanyl
Italy
Analgesics
Cancer Pain
Patient Reported Outcome Measures
Research Personnel
Prospective Studies
Physicians
Equipment and Supplies

Keywords

  • Buprenorphine
  • Cancer pain
  • Opioids
  • Outcome Research

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients : Results from the cancer pain outcome research (CPOR) study group. / Apolone, Giovanni; Corli, Oscar; Negri, Emanuele; Mangano, Simone; Montanari, Mauro; Greco, Maria Teresa.

In: Clinical Journal of Pain, Vol. 25, No. 8, 10.2009, p. 671-682.

Research output: Contribution to journalArticle

Apolone, Giovanni ; Corli, Oscar ; Negri, Emanuele ; Mangano, Simone ; Montanari, Mauro ; Greco, Maria Teresa. / Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients : Results from the cancer pain outcome research (CPOR) study group. In: Clinical Journal of Pain. 2009 ; Vol. 25, No. 8. pp. 671-682.
@article{883062eadf3f4e5a8500642c1946a75a,
title = "Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: Results from the cancer pain outcome research (CPOR) study group",
abstract = "Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60{\%}) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43{\%} it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16{\%} and 17{\%}). About 34{\%} of patients had an improvement of at least 2 points in worst pain, 15{\%} had a 20{\%} improvement in pain relief, and 40{\%} in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.",
keywords = "Buprenorphine, Cancer pain, Opioids, Outcome Research",
author = "Giovanni Apolone and Oscar Corli and Emanuele Negri and Simone Mangano and Mauro Montanari and Greco, {Maria Teresa}",
year = "2009",
month = "10",
doi = "10.1097/AJP.0b013e3181a38f9d",
language = "English",
volume = "25",
pages = "671--682",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients

T2 - Results from the cancer pain outcome research (CPOR) study group

AU - Apolone, Giovanni

AU - Corli, Oscar

AU - Negri, Emanuele

AU - Mangano, Simone

AU - Montanari, Mauro

AU - Greco, Maria Teresa

PY - 2009/10

Y1 - 2009/10

N2 - Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16% and 17%). About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.

AB - Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16% and 17%). About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.

KW - Buprenorphine

KW - Cancer pain

KW - Opioids

KW - Outcome Research

UR - http://www.scopus.com/inward/record.url?scp=70349672833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349672833&partnerID=8YFLogxK

U2 - 10.1097/AJP.0b013e3181a38f9d

DO - 10.1097/AJP.0b013e3181a38f9d

M3 - Article

C2 - 19920716

AN - SCOPUS:70349672833

VL - 25

SP - 671

EP - 682

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 8

ER -